Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Lynparza cut death risk by one-third in adjuvant treatment of germline BRCA-mutated high-risk early breast cancer

By Brian Buntz | March 16, 2022

LynparzaLynparza (olaparib) significantly reduced death risk when treating germline BRCA-mutated high-risk early breast cancer in the Phase 3 OlympiA study, according to AstraZeneca (LON: AZN).

Lynparza recently became the first FDA-approved medicine targeting BRCA mutations in the same type of cancer.

The drug is the first poly(ADP-ribose) polymerase (PARP) inhibitor to show an overall survival benefit in early breast cancer, according to AstraZeneca.

AstraZeneca developed the drug with Merck & Co. (NYSE:MRK), a company known as MSD outside of the U.S.

The OlympiA study showed that olaparib had a statistically significant and clinically meaningful improvement in overall survival (OS) compared to placebo in the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

Patients in the study had received earlier local treatment and standard neoadjuvant or adjuvant chemotherapy.

Participants in the trial who received Lynparza had a three-year survival rate of 92.8% compared to 89.1% for those receiving placebo.

Earlier data from the OlympiA trial were published last year in NEJM.

“OlympiA has now shown that olaparib not only reduced the risk of recurrence but also improved overall survival for women with high-risk early-stage breast cancer and a BRCA1/2 mutation and is an exciting demonstration of the benefits of targeting the specific biology of disease for these women,” said Professor Andrew Tutt, global chair of the OlympiA study, in a statement.

Now approved for ovarian cancer, prostate and pancreatic cancer, Lynparza is also the subject of Phase 3 trials focused on colorectal, endometrial, lung and squamous cell cancers.

In related news, Merck recently announced that it was stopping the KEYLYNK-010 Trial testing Keytruda (pembrolizumab) with Lynparza (olaparib) in patients with metastatic castration-resistant prostate cancer owing to futility.


Filed Under: Oncology
Tagged With: AstraZeneca, Lynparza, Merck
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Novartis in the Pharma 50
Novartis announces tislelizumab helped extend median overall survival in first-line advanced esophageal cancer 
Johnson & Johnson Janssen pharmaceutical business in the Pharma 50
Janssen gets positive CHMP opinion for Imbruvica for adults with untreated chronic lymphocytic leukemia
oncopeptides
Oncopeptides’ Pepaxti wins positive opinion from CHMP for multiple myeloma patients
DNA sequencer
Localizing next-generation sequencing testing for cancer patients

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50